

Fertility preservation in cancer patients: Advances in oocyte and embryo cryopreservation.

Erica Loren*

Department of Obstetrics & Gynecology, University of Toronto, Canada

Introduction

Fertility preservation has become an essential aspect of cancer care, particularly for young patients who wish to retain the possibility of having biological children post-treatment [1]. Advances in oocyte and embryo cryopreservation are now offering promising options for preserving reproductive potential in cancer patients [2].

Oocyte cryopreservation, or egg freezing, has emerged as a viable method for women undergoing cancer treatment [3]. The process involves ovarian stimulation, egg retrieval, and rapid freezing using vitrification, a method that prevents the formation of ice crystals and ensures higher survival rates upon thawing [4]. Unlike earlier slow-freezing techniques, vitrification has significantly improved post-thaw outcomes, including fertilization and live birth rates [5]. Studies published in *Human Reproduction* highlight that vitrified eggs now show success rates comparable to fresh eggs, making this an increasingly preferred option for cancer patients [6].

Embryo cryopreservation is another well-established technique, where fertilized eggs are frozen for future use [7]. This option is ideal for patients with a partner or those who choose donor sperm prior to cancer treatment. Embryo freezing has long been considered the gold standard in fertility preservation due to its proven track record of high success rates. Recent advancements in culture media and freezing protocols have further improved the viability of embryos after thawing, leading to higher implantation and pregnancy success rates [8].

For cancer patients, the timing of fertility preservation is critical, as treatments like chemotherapy and radiation can severely impact ovarian function [9]. Coordination between oncologists and reproductive specialists is essential to ensure that fertility preservation measures do not delay cancer treatment [10].

Conclusion

Advances in oocyte and embryo cryopreservation have transformed fertility preservation for cancer patients, offering hope and flexibility in family planning post-recovery. As techniques continue to improve, these methods are becoming

increasingly accessible and effective, enabling cancer survivors to achieve their reproductive goals.

References

1. Dolmans MM. Recent advances in fertility preservation and counseling for female cancer patients. *Expert Rev Anticancer Ther.* 2018;18(2):115-20.
2. Bagchi A, Woods EJ, Critser JK. Cryopreservation and vitrification: recent advances in fertility preservation technologies. *Expert Rev Med Devices.* 2008;5(3):359-70.
3. Ata B, Chian RC, Tan SL, et al. Cryopreservation of oocytes and embryos for fertility preservation for female cancer patients. *Best Pract Res Clin Obstet Gynaecol.* 2010;24(1):101-12.
4. Qiao J, Li R. Fertility preservation: challenges and opportunities. *Lancet.* 2014;384(9950):1246-7.
5. Chen J, Todorov P, Isachenko E, et al. Construction and cryopreservation of an artificial ovary in cancer patients as an element of cancer therapy and a promising approach to fertility restoration. *Hum Fertil (Camb).* 2022;25(4):651-61.
6. McLaren JF, Bates GW. Fertility preservation in women of reproductive age with cancer. *Am J Obstet Gynecol.* 2012;207(6):455-62.
7. Kappy M, Lieman HJ, Pollack S, et al. Fertility preservation for cancer patients: treatment gaps and considerations in patients' choices. *Arch Gynecol Obstet.* 2021;303:1617-23.
8. Seli E, Tangir J. Fertility preservation options for female patients with malignancies. *Curr Opin Obstet Gynecol.* 2005;17(3):299-308.
9. Ulrich ND, Raja NS, Moravek MB. A review of fertility preservation in patients with breast cancer. *Best Pract Res Clin Obstet Gynaecol.* 2022;82:60-8.
10. Dudzinski DM. Ethical issues in fertility preservation for adolescent cancer survivors: oocyte and ovarian tissue cryopreservation. *J Pediatr Adolesc Gynecol.* 2004;17(2):97-102.

*Correspondence to: Erica Loren, Department of Obstetrics & Gynecology, University of Toronto, Canada. E-mail: loren@ut.cn.ca

Received: 22-Oct-2024, Manuscript No. AAGGS-24-155104; Editor assigned: 23-Oct-2024, Pre QC No. AAGGS-24-155104(PQ); Reviewed: 06-Nov-2024, QC No. AAGGS-24-155104; Revised: 11-Nov-2024, Manuscript No. AAGGS-24-155104(R); Published: 18-Nov-2024, DOI: 10.35841/ajjnr-8.6.231